首页|期刊导航|LabMed Discovery|Reengineering immunotherapeutic responses:ferroptosis-primed radiotherapy converts cold-colorectal tumors into immunotherapy checkpoint inhibitor-sensitive hot lesions

Reengineering immunotherapeutic responses:ferroptosis-primed radiotherapy converts cold-colorectal tumors into immunotherapy checkpoint inhibitor-sensitive hot lesionsOA

中文摘要

While immune checkpoint inhibitors(ICIs)have revolutionized oncology,microsatellite stable(MSS)colorectal cancer(CRC)remains immunologically“cold”and resistant.Ferroptosis,an iron-dependent form of cell death triggered by radiotherapy via reactive oxygen species(ROS)and acyl-CoA synthetase long-chain family member 4(ACSL4),represents a critical vulnerability.Radiotherapy-induced ferroptosis promotes CD8+T-cell recruitment;these T cells secrete interferon-γ(IFN-γ)to further repress solute carrier family 7 member 11(SLC7A11),forming a reciprocal positive feedback loop that amplifies tumor killing.Crucially,we propose a paradigm shift by introducing an inherent“immunosuppressive brake”within this process.Recent evidence has revealed that ferroptotic cancer cells selectively release extracellular glutathione peroxidase 4(eGPX4).As a novel damage-associated molecular pattern(DAMP),eGPX4 binds to the zona pellucida glycoprotein 3(ZP3)receptor on dendritic cells(DCs),activating the cyclic adenosine monophosphate–protein kinase A(cAMP‒PKA)signaling cascade to inhibit 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2(PFKFB2)-mediated glycolysis.This metabolic hijacking impairs DC maturation and subsequent T-cell priming,limiting the systemic efficacy of ferroptosis-inducing therapies.Therefore,we argue that successfully converting“cold”MSS CRC into a“hot”phenotype requires a dual strategy:maximizing ferroptosis induction while simultaneously neutralizing the eGPX4-ZP3 axis.This integrated approach provides a novel translational framework to overcome immunotherapy resistance,offering fresh hope for the majority of CRC patients.

Hang Jia;Le-Qi Zhou;Rong-Bo Wen;Yue Yu;Ning Wang;Tian-Shuai Zhang;Zhi-Ying Peng;Jian-Feng Chen;Guan-Yu Yu;Wei Zhang

Department of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,ChinaDepartment of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,ChinaDepartment of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,ChinaDepartment of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,ChinaDepartment of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,ChinaDepartment of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,ChinaDepartment of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,ChinaCAS Center for Excellence in Molecular Cell Science,Shanghai Institute of Biochemistry and Cell Biology,University of Chinese Academy of Sciences,Chinese Academy of Sciences,Shanghai 200031,ChinaDepartment of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,ChinaDepartment of Colorectal Surgery,Changhai Hospital,Naval Medical University,Shanghai 200433,China

医药卫生

Colorectal cancer(CRC)Ionizing radiation(IR)Immunotherapy checkpoint inhibitor(ICI)FerroptosisTumor immuneTumor microenvironment(TME)

《LabMed Discovery》 2026 (1)

P.23-32,10

financially supported by grants from the National Natural Science Foundation of China(Nos.82272705 and 82203137)the Shanghai“Rising Stars of Medical Talents”Youth Development Program of the Shanghai Municipal Health Commission,China(No.2024-70)the Naval Medical University“Deep Blue”Project Talent Program,the First Affiliated Hospital of Naval Medical University Special Project for Basic Medical Research,China(Nos.2023QD003 and 2023PY04)the First Affiliated Hospital of Naval Medical University Special Project for Clinical Research,China(No.2024LYA02)the Health Care Research Project 2024,China(No.24BJZ10)the Commission Health Industry Clinical Research Project of China(No.20224Y0348).

10.1016/j.lmd.2026.100119

评论